Accès ouvert
2026
article
OpenAlex
Léopoldine Lapierre, Lucie Laemmel, Emilie Bérard, Lucie Rigolot et autres
Azacitidine-venetoclax (AZA-VEN) has become a standard treatment in older or chemotherapy-ineligible AML patients. While the registration trial showed a median overall survival (OS) of 14.7 months, most real-world studies have not reproduced this result. We analyzed treatment patterns, adverse events, responses and …
fr
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Jean Vial, Inès Vergnolle, Laëtitia Largeaud, Lucie Donaty et autres
Abstract IntroductionMRD assessment in AML provides a quantitative approach to define a deeper remission status and refine the risk assessment of postremission relapse. Currently, the two most extensively validated methodologies are multiparameter flow cytometry-based MRD (MFC-MRD) and molecular MRD (Mol-MRD) assessed by …
fr
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Christian Récher, Emilie Bérard, Suzanne Tavitian, Thibaut Leguay et autres
Abstract IntroductionResults from pivotal clinical trials evaluating the combination of intensive chemotherapy (IC) with inhibitors of IDH1, IDH2, menin, FLT3 and BCL2 are expected in the coming years. These results could transform the therapeutic landscape for AML patients (pts) fit for IC. …
fr
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Saniya Kari, Florence Bucciarelli, Thibault Angles, Oster Anne-Cécile et autres
BACKGROUND: The glycoprotein CD226 plays a key role in regulating immune cell function. Soluble CD226 (sCD226) is increased in sera of patients with several chronic inflammatory diseases but its levels in neuroinflammatory diseases such as multiple sclerosis (MS) are unknown. OBJECTIVE: To …
fr
(code pays fourni par la source)